Succeeded in research and development of various therapeutic agents such as’thrombin inhibitors’…Experience in exporting technologies
ADC New Drug Pipeline R&D-Clinical Development Expected to Resist
[팜뉴스=이권구 기자] Aptis Co., Ltd., a new drug development company that possesses the original technology of the ADC (antibody-drug conjugate) platform, has hired Dr. Young-Soo Oh as the head of the research institute (CTO) and vice president.
Young-soo Oh, the new head of the research institute (pictured), graduated from Seoul National University’s Department of Chemistry, received a Ph. Afterwards, he served as a research fellow at LG Life Sciences Research Fellow, Head of Research Division at Scripps Korea Antibody Research Institute, and Vice President of Bioneer New Drug Development. At LegoChemBio, he oversaw the research and development of new drugs, including ADC, as CTO and Executive Vice President.
As a project leader during his tenure at LG Life Sciences, the new head of the research institute has successfully researched and developed the oral anticoagulant’Thrombin Inhibitor’ and the liver disease treatment’Caspase Inhibitor’. (Currently Pfizer) has experience in exporting technology to Gilead, a global bio company.
During his tenure at LegoChemBio, he focused on ADC R&D and exported Her2 ADC to Fosun, one of the largest pharmaceutical companies in China, and signed a research license agreement with Takeda Oncology to provide joint R&D and ADC platform technology Exported.
Based on the experience of leading the R&D of new drugs, as well as the experience of exporting technology, Aptis is planning to lead the R&D of new ADCs.
Sang-jeon Sang-jeon, CEO of Aptis, said, “With the joining of the new research center director Oh Young-soo, Vice President Choi Won (CSO) from Severance Hospital, who has extensive clinical development experience in Merck (MSD) and LG Life Sciences, joined Aptis last year and researched and developed ADC new drug pipelines. It is expected that both clinical development and clinical development will gain momentum. “Based on the success of attracting investment in Series B with a company value of 55 billion won at the beginning of this year, clinical and ADC development cooperation with global CRO and CDMO companies will also begin soon.” Told.
Aptis is a bio company developing new drugs with high’Therapeutic Index’ for indications such as anti-cancer and immune diseases based on the patented ADC platform technology. It is evaluated as having an advantage in terms of immunogenicity and CMC because it has site-specific properties for and does not require antibody mutation, so existing antibodies can be used as they are.
Copyright © Farm News Unauthorized reproduction and redistribution prohibited